American Century Companies Inc. purchased a new stake in shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 36,477 shares of the biotechnology company’s stock, valued at approximately $249,000. American Century Companies Inc. owned about 0.07% of Pieris Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. BlackRock Inc. grew its holdings in Pieris Pharmaceuticals by 4.4% during the fourth quarter. BlackRock Inc. now owns 1,596,382 shares of the biotechnology company’s stock valued at $12,053,000 after purchasing an additional 67,895 shares during the last quarter. Millennium Management LLC grew its holdings in Pieris Pharmaceuticals by 57.9% during the fourth quarter. Millennium Management LLC now owns 699,771 shares of the biotechnology company’s stock valued at $5,283,000 after purchasing an additional 256,622 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Pieris Pharmaceuticals by 63.7% during the fourth quarter. Renaissance Technologies LLC now owns 650,100 shares of the biotechnology company’s stock valued at $4,908,000 after purchasing an additional 253,000 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in Pieris Pharmaceuticals during the fourth quarter valued at approximately $3,370,000. Finally, TIAA CREF Investment Management LLC grew its holdings in Pieris Pharmaceuticals by 25.1% during the fourth quarter. TIAA CREF Investment Management LLC now owns 272,287 shares of the biotechnology company’s stock valued at $2,056,000 after purchasing an additional 54,710 shares during the last quarter. Institutional investors own 62.85% of the company’s stock.

Several equities analysts have commented on PIRS shares. ValuEngine upgraded Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. BidaskClub upgraded shares of Pieris Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, February 5th. HC Wainwright set a $12.00 price objective on shares of Pieris Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, February 9th. Jefferies Group started coverage on shares of Pieris Pharmaceuticals in a research note on Monday, March 19th. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, Evercore ISI started coverage on shares of Pieris Pharmaceuticals in a research note on Monday, March 19th. They issued an “outperform” rating and a $13.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $12.33.

In related news, insider Orbimed Advisors Llc sold 1,000,000 shares of the firm’s stock in a transaction on Monday, April 30th. The stock was sold at an average price of $6.35, for a total value of $6,350,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James A. Geraghty bought 10,000 shares of Pieris Pharmaceuticals stock in a transaction that occurred on Tuesday, May 15th. The stock was purchased at an average cost of $5.75 per share, with a total value of $57,500.00. Following the completion of the transaction, the director now owns 20,000 shares of the company’s stock, valued at $115,000. The disclosure for this purchase can be found here. Company insiders own 4.05% of the company’s stock.

Shares of Pieris Pharmaceuticals opened at $5.62 on Friday, MarketBeat Ratings reports. The firm has a market capitalization of $315.21 million, a PE ratio of -14.05 and a beta of 1.72. Pieris Pharmaceuticals Inc has a 1 year low of $4.11 and a 1 year high of $9.75.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.14). The company had revenue of $4.15 million during the quarter, compared to analyst estimates of $11.39 million. Pieris Pharmaceuticals had a negative return on equity of 96.56% and a negative net margin of 65.40%. research analysts expect that Pieris Pharmaceuticals Inc will post -0.48 EPS for the current year.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Want to see what other hedge funds are holding PIRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pieris Pharmaceuticals Inc (NASDAQ:PIRS).

Institutional Ownership by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.